CRTX News and Press, Cortexyme Inc. From 05/06/20

  Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel, disease-modifying therapeutic approach to treat what it believes to be a key underlying cause of Alzheimer’s (AD) and other degenerative diseases, today announced the publication ...

-- Presentation to be webcast on Cortexyme’s website -- Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat what it believes to be a key underlying cause of Alzheimer’s and other deg...

-- New results demonstrate P. gingivalis’ ability to infect neurons and cause characteristic Alzheimer’s pathology -- Cortexyme’s lead compound, COR388, targets gingipains produced by P. gingivalis and is currently under investigation in the Phase 2/3 GAIN Trial ...

Medtronic Gets Patent Challenge from Axonics Medtronic Plc ( MDT ) saw a small setback as Axonics Modulation Technologies filed a petition with the United States Patents and Trademark Office against one of its patents. The petitions contest the validity of Medtronic's patent related to s...

Cortexyme (NASDAQ: CRTX ): Q4 GAAP EPS of -$0.46 misses by $0.08 . Cash, cash equivalents, and short and long-term marketable securities of $116.6M. Press Release More news on: Cortexyme, Inc., Earnings news and commentary, Healthcare stocks news,

— Following initial public offering and private placement, Cortexyme is well capitalized and focused on high quality execution of the Phase 2/3 GAIN Trial — Interim analysis for the GAIN Trial on track to be completed before year-end 2020, with top-line results from stud...

- Sub-study shows greater than 90% of enrolled patients have moderate to severe periodontal disease, indicating relevance to mechanism of action against P. gingivalis - Interim analysis of the Phase 2/3 GAIN Trial expected to occur before year-end 2020 Cortexyme, Inc. (Nasdaq: CR...

Thinly traded Cortexyme ( CRTX +4.4% ) is up, albeit on turnover of only 79K shares, in reaction to its update on lead candidate COR388, currently being evaluated in a Phase 2/3 clinical trial, GAIN , in patients with mild-to-moderate Alzheimer's disease dementia. More news on: Cortex...

- Interim analysis in the Phase 2/3 GAIN Trial expected to occur in Q4 2020 Cortexyme, Inc. (Nasdaq: CRTX) today provided an update on its clinical development plans for COR388, the company’s lead investigational medicine in development for mild to moderate Alzheimer’s di...

Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat Alzheimer’s and other degenerative diseases, today announced that it has closed its private placement offering. The Company issued 2,500,000 sha...